Research Paper Volume 14, Issue 19 pp 7941—7958
ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer
Figure 6. The relationship between ERAP2 expression and gemcitabine resistance. (A) Cell viability assay in BxPC-3 and PANC-1cell lines treated with gemcitabine. (B) The Protein levels of ERAP2 in BxPC-3 and PANC-1 cell lines treated with gemcitabine were assessed by western blot. (C) The mRNA levels of ERAP2 in BxPC-3 and PANC-1cell lines treated with gemcitabine were quantified by qRT-PCR. Data were shown as the mean ± SD of three independent experiments (*p < 0.05, **p < 0.01 and ***p < 0.001).